Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)

This study tests the safety and effectiveness of tenalisib — a targeted oral drug — in people with metastatic triple-negative breast cancer (TNBC), an aggressive form of breast cancer that does not respond to hormone therapies or HER2-targeted drugs and has limited treatment options. **You may be eligible if...** - You have triple-negative breast cancer confirmed by biopsy - Your cancer has spread to other parts of the body (metastatic) - You have received between 1 and 3 prior chemotherapy regimens for metastatic disease - You have at least one measurable tumor (not bone-only disease) - You are in reasonably good health (ECOG performance status 0–2) **You may NOT be eligible if...** - You have active brain metastases - You have received more than 3 prior chemotherapy regimens in the metastatic setting - You have only bone metastases with no other measurable disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.